To estimate and validate the size of the worldwide cancer immunotherapy market, as well as the size of many other dependent submarkets, top-down and bottom-up methodologies were utilised. In the top-down technique, the overall market size was utilised to estimate the sizes of various particular markets (specified in the market segmentation by type, application, end user, and area) using percentage splits from secondary and primary research. To validate the market segment revenues acquired, the bottom-up technique was also used (where available) for data gathered from secondary research. Secondary sources for this research study included government publications such as white papers; articles from recognised authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. To acquire and verify essential information, as well as to estimate the prospects of the cancer immunotherapy industry, primary sources such as specialists from relevant industries and suppliers were questioned.
Cancer immunotherapy is a type of cancer treatment that improves the immune system’s ability to combat cancer. This therapy is superior to the previous method because it gives long-term cancer protection, has less side effects, and addresses a broader spectrum of cancers. Cancer immunotherapy is used to treat a variety of malignancies, including melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head and neck cancer, and others. Immunotherapy works by directing the immune system’s attention to cancer-specific targets, engaging the immune system to mobilize the target, and inducing a response capable of eliminating cancer cells.
Research Methodology:
After secondary research provided a fundamental understanding of the worldwide Cancer Immunotherapy Market scenario, extensive primary research was carried out. A number of primary interviews were carried out with industry experts from the supply and demand sides, including C- and D-level executives, product managers, and marketing and sales managers of major manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering Cancer Immunotherapy Market, as well as personnel from academia, research, and CROs. These interviews were conducted across five major regions: North America, Europe, Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Participants from the supply-side and demand-side participated in about 70% and 30% of the primary interviews, respectively. Through the use of questionnaires, emails, online surveys, in-person interviews, and phone interviews, this main data was gathered.
The segmentation coverage of the study is provided below.
Cancer Immunotherapy Market based on Type:
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulators
Cancer Immunotherapy Market based on Application:
- Lung Cancer
- Breast Cancer
- Head and Neck Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma
- Others
Cancer Immunotherapy Market based on End User:
- Hospitals
- Clinics & Others
Cancer Immunotherapy Market based on Geography:
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa (MEA)
- UAE
- Turkey
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
The cancer immunotherapy market is divided into four categories: technology type, application, end-user, and geography. The market is segmented by technology type into monoclonal antibodies, cytokines & immunomodulators, and others. Monoclonal antibodies retained the greatest share in 2020, owing to an increase in their use for cancer immunotherapy, since they display distinct qualities where the immune system may be controlled and so they can activate or inhibit the molecules targeted on the immune system. Furthermore, monoclonal antibodies stimulate the anticancer immune response.
The cancer immunotherapy market is divided into five applications: lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others. The lung cancer market held the biggest share in 2020 and is likely to lead the market during the study period due to the high prevalence of lung cancer worldwide and an increase in awareness programmes about the need for early lung cancer therapies.
The market is divided into three segments based on end user: hospitals, cancer research centres, and clinics. Due to the widespread usage of cancer immunotherapy in hospitals, hospitals held the greatest market share of the cancer immunotherapy market in 2020, and this category is expected to increase at the fastest rate over the study period. Furthermore, increased demand for hospitals is expected to drive category growth during the projection period. Furthermore, hospitals will have the greatest CAGR of 14.4% during the predicted period.
The cancer immunotherapy market is divided into four regions: North America, Europe, Asia-Pacific, and Latin America. In 2020, North America contributed the most income. This is due to a sharp increase in healthcare spending, a greater emphasis on maintaining the greatest healthcare system, and an increase in cancer incidence worldwide. However, Asia-Pacific is expected to develop at the fastest CAGR throughout the research period, owing to an increase in healthcare spending, an increase in per capita income, and improvements in healthcare infrastructure. Furthermore, due to the region’s infrastructural development and increased cancer occurrences, Europe is predicted to obtain the second biggest market share throughout the projection period.
- This report illustrates the most vital attributes of the Cancer Immunotherapy Market, which are driving and providing opportunities.
- This research gives an in-depth analysis of the Cancer Immunotherapy Market growth on the basis of several segments in the market.
- This report presents the predictions of the past and present trends of the Cancer Immunotherapy Market.
- This study also presents the competitive analysis, such as key strategies and capabilities of major players of the Cancer Immunotherapy Market.
List of Tables
TABLE 1. CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 2. CANCER IMMUNOTHERAPY MARKET VALUE FOR MONOCLONAL ANTIBODIES, BY GEOGRAPHY , 2021-2030 (USD BILLION)
TABLE 3. CANCER IMMUNOTHERAPY MARKET VALUE FOR CANCER VACCINES, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 4. CANCER IMMUNOTHERAPY MARKET VALUE FOR CHECKPOINT INHIBITORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 5. CANCER IMMUNOTHERAPY MARKET VALUE FOR IMMUNOMODULATORS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 6. CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 7. CANCER IMMUNOTHERAPY MARKET VALUE FOR LUNG CANCER, 2021-2030 (USD BILLION)
TABLE 8. CANCER IMMUNOTHERAPY MARKET VALUE FOR BREAST CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 9. CANCER IMMUNOTHERAPY MARKET VALUE FOR HEAD AND NECK CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 10. CANCER IMMUNOTHERAPY MARKET VALUE FOR PROSTATE CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 11. CANCER IMMUNOTHERAPY MARKET VALUE FOR COLORECTAL CANCER, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 12. CANCER IMMUNOTHERAPY MARKET VALUE FOR MELANOMA, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 13. CANCER IMMUNOTHERAPY MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 14. CANCER IMMUNOTHERAPY MARKET VALUE, BY END USER, 2021-2030 (USD BILLION)
TABLE 15. CANCER IMMUNOTHERAPY MARKET VALUE FOR Hospitals, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 16. CANCER IMMUNOTHERAPY MARKET VALUE FOR Clinics & Others, BY GEOGRAPHY, 2021-2030 (USD BILLION)
TABLE 17. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 18. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 19. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 20. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 21. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 22. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 23. U.S CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 24. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 25. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 26. CANADA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 27. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 28. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 29. MEXICO CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 30. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 31. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 32. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 33. EUROPE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 34. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 35. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 36. GERMANY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 37. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 38. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 39. U.K CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 40. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 41. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 42. FRANCE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 43. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 44. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 45. ITALY CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 46. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 47. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 48. SPAIN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 49. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 50. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 51. ROE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 52. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY COUNTRY, 2021-2030 (USD BILLION)
TABLE 53. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 54. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 55. ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 56. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 57. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 58. CHINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 59. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 60. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 61. INDIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 62. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 63. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 64. JAPAN CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 65. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 66. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 67. REST OF APAC CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 68. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 69. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 70. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 71. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 72. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 73. BRAZIL CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 74. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 75. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 76. ARGENTINA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 77. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 78. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 79. MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 80. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 81. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 82. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 83. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 84. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 85. UAE CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 86. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY TYPE, 2021-2030 (USD BILLION)
TABLE 87. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY APPLICATION, 2021-2030 (USD BILLION)
TABLE 88. REST OF MIDDLE EAST AND AFRICA CANCER IMMUNOTHERAPY MARKET VALUE, BY END USERS, 2021-2030 (USD BILLION)
TABLE 89. AMGEN, INC. : FINANCIALS
TABLE 90. AMGEN, INC. : PRODUCTS & SERVICES
TABLE 91. AMGEN, INC. : RECENT DEVELOPMENTS
TABLE 92. ASTRAZENECA, PLC: FINANCIALS
TABLE 93. ASTRAZENECA, PLC: PRODUCTS & SERVICES
TABLE 94. ASTRAZENECA, PLC: RECENT DEVELOPMENTS
TABLE 95. BAYER AG: FINANCIALS
TABLE 96. BAYER AG: PRODUCTS & SERVICES
TABLE 97. BAYER AG: RECENT DEVELOPMENTS
TABLE 98. BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS
TABLE 99. BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS & SERVICES
TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: RECENT DEVELOPMENTS
TABLE 101. ELI LILY AND COMPANY: FINANCIALS
TABLE 102. ELI LILY AND COMPANY: PRODUCTS & SERVICES
TABLE 103. ELI LILY AND COMPANY: RECENT DEVELOPMENTS
TABLE 104. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): FINANCIALS
TABLE 105. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): PRODUCTS & SERVICES
TABLE 106. F. HOFFMANN-LA ROCHE, LTD. (GENENTECH, INC.): RECENT DEVELOPMENTS
TABLE 107. PFIZER, INC. : FINANCIALS
TABLE 108. PFIZER, INC. : PRODUCTS & SERVICES
TABLE 109. PFIZER, INC. : DEVELOPMENTS
TABLE 110. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): FINANCIALS
TABLE 111. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): PRODUCTS & SERVICES
TABLE 112. JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC): RECENT DEVELOPMENTS
TABLE 113. MERCK KGAA: FINANCIALS
TABLE 114. MERCK KGAA: PRODUCTS & SERVICES
TABLE 115. MERCK KGAA: RECENT DEVELOPMENTS
TABLE 116. NOVARTIS AG: FINANCIALS
TABLE 117. NOVARTIS AG: PRODUCTS & SERVICES
TABLE 118. NOVARTIS AG: RECENT DEVELOPMENTS
